drugset / Trial / NCT00243074

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

NCT00243074

Phase 2 Completed 54 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Timeline

Start
2005-11
Primary completion
2010-04
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule Oral